Susquehanna International Group, LLP Axsome Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $5.04 Million - $6.12 Million	63,900 Added 34.21%	250,700 $22.5 Million
Q2 2024 Aug 15, 2024	BUY	$65.72 - $80.5 $1.91 Million - $2.33 Million	29,000 Added 18.38%	186,800 $15 Million
Q1 2024 May 07, 2024	SELL	$69.39 - $97.64 $11.3 Million - $15.9 Million	-163,200 Reduced 50.84%	157,800 $12.6 Million
Q4 2023 Feb 14, 2024	BUY	$57.42 - $83.61 $924,462 - $1.35 Million	16,100 Added 5.28%	321,000 $25.5 Million
Q3 2023 Nov 14, 2023	SELL	$69.25 - $82.21 $3.12 Million - $3.7 Million	-45,000 Reduced 12.86%	304,900 $21.3 Million
Q2 2023 Aug 11, 2023	SELL	$58.41 - $90.35 $1.52 Million - $2.36 Million	-26,100 Reduced 6.94%	349,900 $25.1 Million
Q1 2023 May 16, 2023	SELL	$58.39 - $75.0 $8.92 Million - $11.5 Million	-152,700 Reduced 28.88%	376,000 $23.2 Million
Q4 2022 Feb 14, 2023	SELL	$39.94 - $79.72 $1.52 Million - $3.03 Million	-38,000 Reduced 6.71%	528,700 $40.8 Million
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $10.9 Million - $21 Million	300,900 Added 113.21%	566,700 $25.3 Million
Q2 2022 Aug 15, 2022	SELL	$21.74 - $46.75 $2.7 Million - $5.81 Million	-124,200 Reduced 31.85%	265,800 $10.2 Million
Q1 2022 May 16, 2022	SELL	$23.7 - $41.39 $1.55 Million - $2.72 Million	-65,600 Reduced 14.4%	390,000 $16.1 Million
Q4 2021 Feb 14, 2022	BUY	$30.7 - $43.36 $3.41 Million - $4.82 Million	111,100 Added 32.25%	455,600 $17.2 Million
Q3 2021 Nov 15, 2021	BUY	$19.91 - $68.26 $4.44 Million - $15.2 Million	222,900 Added 183.31%	344,500 $11.4 Million
Q2 2021 Aug 11, 2021	BUY	$50.63 - $73.5 $2.27 Million - $3.29 Million	44,800 Added 58.33%	121,600 $8.2 Million
Q1 2021 May 17, 2021	SELL	$55.91 - $81.44 $2.56 Million - $3.72 Million	-45,700 Reduced 37.31%	76,800 $4.35 Million
Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $4.4 Million - $5.74 Million	-66,400 Reduced 35.15%	122,500 $9.98 Million
Q3 2020 Nov 16, 2020	BUY	$68.34 - $85.84 $1.29 Million - $1.62 Million	18,900 Added 11.12%	188,900 $13.5 Million
Q2 2020 Aug 14, 2020	SELL	$49.87 - $98.69 $5.17 Million - $10.2 Million	-103,700 Reduced 37.89%	170,000 $14 Million
Q1 2020 May 15, 2020	SELL	$41.2 - $101.31 $2.99 Million - $7.34 Million	-72,500 Reduced 20.94%	273,700 $16.1 Million
Q4 2019 Feb 14, 2020	BUY	$16.71 - $106.24 $1.55 Million - $9.87 Million	92,900 Added 36.68%	346,200 $35.8 Million
Q3 2019 Nov 14, 2019	BUY	$20.24 - $29.16 $406,823 - $586,116	20,100 Added 8.62%	253,300 $5.13 Million
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $1.5 Million - $2.86 Million	111,200 Added 91.15%	233,200 $6.01 Million
Q1 2019 May 15, 2019	BUY	$2.63 - $16.34 $276,676 - $1.72 Million	105,200 Added 626.19%	122,000 $1.74 Million
Q4 2018 Feb 14, 2019	BUY	$2.0 - $4.15 $33,600 - $69,720	16,800 New	16,800 $47,000
Q3 2018 Nov 14, 2018	SELL	$2.3 - $3.55 $23,000 - $35,500	-10,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$2.15 - $3.6 $57,835 - $96,840	-26,900 Reduced 72.9%	10,000 $32,000
Q4 2017 Feb 14, 2018	BUY	$4.45 - $6.2 $164,205 - $228,780	36,900	36,900 $207,000

Others Institutions Holding AXSM

# of Institutions

326

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.99B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account